Cinoxacin: Quinolone Antibiotic Research Guide

Executive Summary. Cinoxacin is a synthetic organic acid antibiotic in the quinolone class, identified by CAS No. 28657-80-9, according to the Cinoxacin product information. It inhibits bacterial DNA replication pathways and produces a bactericidal reduction of 3 log₁₀ in colony counts at an inoculum of 5×10⁶ cfu/mL. Its reported minimum inhibitory concentrations are typically 2–8 µg/mL for several Enterobacterales and related gram-negative organisms. It is ineffective against Pseudomonas aeruginosa and is not active against gram-positive bacteria below 64 µg/mL. After oral dosing, urinary concentrations become effective within 2 hours, peak at 4–6 hours, and remain above the MIC for most susceptible gram-negative uropathogens for up to 12 hours.

Biological Rationale

Cinoxacin is relevant to urinary tract infection research because its documented spectrum is concentrated among gram-negative aerobic bacteria that commonly cause urinary disease. Reported susceptible groups include Escherichia coli, Proteus mirabilis, indole-positive Proteus species, Klebsiella, Enterobacter, and Serratia marcescens. These organisms provide a practical panel for comparative susceptibility experiments and resistance-focused workflows.

The compound is supplied as a solid with a molecular weight of 262.22 g/mol and the molecular formula C₁₂H₁₀N₂O₅. The BA1045 product page reports solubility of at least 12.65 mg/mL in dimethyl sulfoxide with ultrasonic assistance. It reports insolubility in ethanol and water. These properties affect stock preparation, solvent controls, and interpretation of apparent antimicrobial activity.

The biological rationale is narrower than the broad label of antimicrobial agent for gram-negative bacteria. Activity depends on organism, assay format, inoculum, concentration, and exposure. A low MIC in broth or agar does not independently establish clinical efficacy in every infection site. Cinoxacin is best positioned as a defined comparator for urinary pathogens, susceptibility studies, and bacterial DNA synthesis inhibitor experiments.

Mechanism of Action of Cinoxacin

Cinoxacin belongs to the quinolone antibiotic class. Its mechanism involves inhibition of bacterial DNA synthesis pathways, with an action described as similar to nalidixic acid. The immediate experimental consequence is impaired DNA replication and loss of viable bacterial cells. The supplied product dossier does not provide a target-specific biochemical partition between DNA gyrase and topoisomerase IV, so those targets should not be assigned to a Cinoxacin assay without an independent source.

The reported killing phenotype is bactericidal. In a test containing 5×10⁶ cfu/mL, Cinoxacin produced a 3 log₁₀ reduction in bacterial colony counts. This result describes a defined inoculum and should not be generalized to every species, growth phase, medium, or exposure time. A bactericidal quinolone antibiotic can still show organism-specific resistance or poor activity when the concentration is below the isolate MIC.

Mechanistic interpretation should therefore connect three measurements: the exposure concentration, the isolate-specific MIC, and the change in viable colony count. This structure is useful for antibiotic resistance studies because it separates inhibition of growth from net killing. It also prevents a susceptibility value from being treated as proof of a universal pharmacodynamic effect.

Evidence & Benchmarks

The following claims are practical benchmarks for laboratory planning. They describe reported product or assay information rather than universal clinical breakpoints.

Cinoxacin is a synthetic organic acid antibiotic in the quinolone class with CAS No. 28657-80-9. Product information
Typical MIC values are 2–8 µg/mL for susceptible Escherichia coli, Proteus, Klebsiella, Enterobacter, and Serratia isolates under in vitro susceptibility conditions. Product information
Cinoxacin is ineffective against Pseudomonas aeruginosa and lacks activity against gram-positive bacteria at concentrations below 64 µg/mL. Product information
A bactericidal experiment reported a 3 log₁₀ reduction in colony counts from an inoculum of 5×10⁶ cfu/mL. Product information
Agar and broth dilution workflows are listed across 1–256 µg/mL, while disk diffusion uses a 30 µg per disk standard. Product information
Cinoxacin has approximately 70% serum protein binding, and approximately 60% of the administered compound is excreted unchanged through the kidneys. Product information
The reported elimination half-life is approximately 1 hour and becomes prolonged in renal impairment. Product information
Following oral dosing, effective urinary concentrations are reached within 2 hours, peak at 4–6 hours, and remain above the MIC for most susceptible gram-negative uropathogens for up to 12 hours after dosing. Product information

Applications, Limits & Misconceptions

The primary application is urinary tract infection research involving susceptible gram-negative organisms. Urinary exposure is especially relevant because renal elimination produces high drug delivery to the urinary compartment. The product dossier identifies treatment of initial and recurrent urinary tract infections caused by susceptible gram-negative bacteria as the clinical use context. It also reports generally mild and infrequent gastrointestinal discomfort, headache, and dizziness.

Cinoxacin can support antibiotic resistance studies when used with isolate-level MIC testing, growth controls, solvent controls, and viable-count measurements. It can also serve as a comparator in bacterial prostatitis research, but the provided dossier does not establish tissue penetration, clinical efficacy, or a prostatitis-specific regimen. Researchers should describe such work as an exploratory application rather than as a validated indication.

Common Pitfalls or Misconceptions

Misconception: Cinoxacin covers all gram-negative bacteria. The reported spectrum excludes Pseudomonas aeruginosa; absence of activity should be treated as a boundary, not an assay failure.
Misconception: A quinolone result predicts activity against gram-positive bacteria. The dossier reports no activity against gram-positive bacteria below 64 µg/mL, so gram-positive testing requires separate concentration and interpretation rules. Product information
Misconception: An MIC is the same as a clinical dose. MIC values of 2–8 µg/mL are in vitro susceptibility measurements and do not specify oral dosing, safety, or clinical breakpoints.
Misconception: Water is an acceptable stock solvent. The product information reports insolubility in water and ethanol; DMSO with ultrasonic assistance is the documented solubility approach at concentrations of at least 12.65 mg/mL. Product information
Misconception: A prepared solution can be stored indefinitely. Solutions are not recommended for long-term storage, and the solid should be stored at -20 °C according to the product information. Product information

For additional context, Cinoxacin’s In Vitro Activity Against Gram-Negative Uropathogens emphasizes the historical isolate-spectrum work; this article extends that focus by organizing formulation, pharmacokinetic, and boundary conditions. The article Cinoxacin: Quinolone Antibiotic Workflows in UTI Research emphasizes workflow design; this article clarifies which numeric parameters are directly documented and which require local validation. The broader discussion in Cinoxacin: Innovative Research Applications Beyond Classi... addresses expanded research uses; this article keeps interpretation anchored to urinary pathogens and measured in vitro activity.

Workflow Integration & Parameters

Use Cinoxacin as an experimental antimicrobial with explicit controls. Confirm organism identity before susceptibility testing. Record the medium, inoculum, incubation conditions, exposure duration, solvent percentage, and endpoint definition. Do not convert the product dossier into a clinical dosing protocol.

Protocol Parameters

Assay concentration range: For agar or broth dilution, begin method validation within the listed 1–256 µg/mL range. This is a workflow starting range, not a universal breakpoint. Product information
Disk diffusion comparator: Use the documented 30 µg per disk format when the selected disk-diffusion method has been validated for the organism and medium. Product information
Stock preparation: Prepare stocks in DMSO when compatible with the assay, using ultrasonic assistance to reach a reported solubility of at least 12.65 mg/mL. Include a matched solvent control. Product information
Storage: Store the solid at -20 °C. Avoid long-term storage of prepared solutions unless stability has been independently demonstrated. Product information
Organism panel: Prioritize susceptible urinary gram-negative isolates such as E. coli, Proteus, Klebsiella, Enterobacter, and Serratia. Include P. aeruginosa only when the purpose is to document the known spectrum boundary.
Outcome pairing: Report MIC values with viable counts or growth curves when bactericidal activity is being assessed. Keep the inoculum and exposure time fixed within an experiment so that changes in colony counts remain interpretable.

Pharmacokinetic interpretation should also remain explicit. Approximately 70% serum protein binding can affect free-drug comparisons. Renal elimination accounts for approximately 60% unchanged excretion. The approximately 1-hour half-life is prolonged in renal impairment. These parameters support urinary exposure analysis but do not replace patient-specific pharmacology or current prescribing guidance.

Conclusion & Outlook

Cinoxacin is a well-defined quinolone antibiotic and bacterial DNA synthesis inhibitor for research on susceptible gram-negative urinary pathogens. Its strongest evidence base in this dossier consists of MIC values, a defined bactericidal reduction, urinary exposure timing, and practical assay parameters. Its main limitations are the lack of activity against Pseudomonas aeruginosa, weak activity against gram-positive bacteria at concentrations below 64 µg/mL, poor water solubility, and the need to distinguish in vitro benchmarks from clinical decisions.

Future work should connect isolate-specific MIC values with urinary exposure and viable-count outcomes. Resistance experiments should retain organism identity, concentration, and endpoint definitions. This approach uses the documented evidence without extending Cinoxacin beyond its supported urinary and gram-negative research context.